Navigation Links
Singapore scientist wins coveted Chen New Investigator Award 2013
Date:4/18/2013

ium of multiple A*STAR Research Institutes and public healthcare centres that is driving Singapore's concerted effort to venture into stratified medicine. Besides identifying new biomarkers and technology for personalized treatment, POLARIS will also embark on education, outreach and engagement efforts.

In addition to his appointment in GIS, Dr Tan is also a Professor in the Cancer and Stem Cell Biology Program at Duke-NUS Graduate Medical School, and a Senior Principal Investigator at the Cancer Science Institute of Singapore at the National University of Singapore (NUS).

Dr Tan said, "I am deeply humbled and grateful to receive the Chen Award. This honour would not have been possible without the tireless support of my research team and our many collaborators throughout Singapore. We will redouble our efforts to translate our discoveries into applications that significantly improve health outcomes for patients in Singapore and the region."

GIS Executive Director Prof Ng Huck Hui said, "GIS is truly honoured by the recognition given to Patrick for all the important work he does in Singapore. In recent years, stratified oncology and personalized medicine have become significantly important because we want to make sure that each patient receives the best and most suitable therapeutic options available. Also, with the set-up of POLARIS under Dr Tan's leadership, there will be even closer collaborations with other research entities and clinicians toward this end. We are extremely proud of his achievements."


'/>"/>

Contact: Winnie Lim
limcp2@gis.a-star.edu.sg
656-808-8013
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Regular Distributor Conference Calls Planned For Marketing Xocolate International
2. Xocai Mayalsia
3. Xocai Taiwan
4. Xocai Singapore
5. Singapore scientists identify new biomarker for cancer in bone marrow
6. One Stop Skin Care Solutions for Dermatological Conditions in Singapore
7. National Cancer Centre Singapore scientists discover p53 mutation hinders cancer treatment response
8. Singapore scientists led by A*STARs GIS identify 4 mechanisms that contribute to gastric cancers
9. EP Global Communications, Inc, EPGL Medical Begins Selling MPDD Devices, Singapore Distributor Secures First 1,000 Units Off Assembly Line
10. Singapore clinician-scientists identify new type of deadly lymphoma
11. Dissertation Help launches services for DBA consulting in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... to normalize up, to 600,000 internally displaced residents of Baghdad into ... ... 6 Dr. Said Hakki, president,of the Iraqi Red Crescent Organization ... discuss the organization,s,Neighborhood Reconstruction Program (NRP) to immediately assist up to,600,000 ...
... Some of the UKs leading experts in location technologies ... hospitals are already improving the efficiency and quality of ... between hardware and software applications, and a lack of ... NHS is not benefiting as much as it could. ...
... GREAT RIVER, N.Y., May 6 VirtualCDO acted ... the sale of the company to Lawson,Software (St. ... management,software and services, assisted healthcare, hospitality and government,service ... enterprise,software and enterprise management services to some 4,000 ...
... Patients, Safety,Concerns, But Lack Confidence About Best Ways ... As patient safety,incidents in America,s hospitals continue ... hospital CEOs feel strongly confident about practices in,place ... the VHA Foundation,today formally launched the "Health Care ...
... Institute (HMRI) and Xstrata Coal will today announce a significant ... asthma in the Hunter and beyond. , Xstrata Coal has ... a newly recognised type of asthma which accounts for 50 ... Asthma Research Fellow, Dr Katie Baines from the University of ...
... experience can be deadly, say authors of a new survey ... often underestimate their level of driving experience, putting them at ... , And while many teens recognize that drinking and driving ... distraction posed by having friends in the car. , "We ...
Cached Medicine News:Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 2Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 3Health News:Location! Location! Location technologies are improving NHS care 2Health News:VirtualCDO Acts as M&A Advisor in Sale of VasTech to Lawson Software 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 3Health News:Many Teen Drivers Don't Think They're Inexperienced 2Health News:Many Teen Drivers Don't Think They're Inexperienced 3
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Shire plc (LSE: SHP,Nasdaq: SHPGY), the global ... scientific meeting findings from analyses of pivotal ... compound is an,investigational once-daily medication, which is ... of Attention Deficit Hyperactivity Disorder,(ADHD). The data ...
... and 2 Data Expected at ASCO in June ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... has completed patient enrollment in,its Phase 2 clinical ... of metastatic colorectal cancer (CRC). Early,data from this ...
Cached Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
...
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Medicine Products: